GLYCOMIMETICS INC
For the period ended Dec 31, 2024. Filed Feb 13, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 13, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | ||
|---|---|---|---|
| | | GLYCOMIMETICS, INC. | |
| | | ||
| | | By: | /s/ Harout Semerjian |
| | | Harout Semerjian | |
| | | President and Chief Executive Officer | |
February 13, 2025
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Harout Semerjian and Brian M. Hahn, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of GlycoMimetics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| | | |
|---|---|---|
| Signature | Title | Date |
| | | |
| /s/ Harout Semerjian Harout Semerjian | President, Chief Executive Officer and Director(Principal Executive Officer) | February 13, 2025 |
| | | |
| /s/ Brian M. Hahn Brian M. Hahn | Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer) | February 13, 2025 |
| | | |
| /s/ Patricia S. Andrews Patricia S. Andrews | Director | February 13, 2025 |
| | | |
| /s/ Mark A. Goldberg, M.D. Mark A. Goldberg, M.D. | Director | February 13, 2025 |
| | | |
| /s/ Scott T. Jackson Scott T. Jackson | Director | February 13, 2025 |
| | | |
| /s/ Daniel M. Junius Daniel M. Junius | Director | February 13, 2025 |
| | | |
| /s/ Rachel K. King Rachel K. King | Director | February 13, 2025 |
| | | |
| /s/ Scott Koenig, M.D., Ph.D. Scott Koenig, M.D., Ph.D. | Director | February 13, 2025 |
| | | |
| /s/ Timothy Pearson Timothy Pearson | Director | February 13, 2025 |
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 84 |
|---|---|
| Balance Sheets as of December 31, 2024 and 2023 | 85 |
| Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023 | 86 |
| Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023 | 87 |
| Statements of Cash Flows for the years ended December 31, 2024 and 2023 | 88 |
| Notes to Financial Statements | 89 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.